A. Etiology, pathogenesis, risk factors, clinical features, points of convergence and differences in:
- Alzheimer’s Disease (AD) including non-cognitive aspects
- Parkinson’s Disease (PD), PD dementia, atypical PD & non motor symptoms in PD
- Minimal cognitive impairment (MCI) and Age-Associated Memory Impairment (AAMI)
- Vascular dementia (VAD)
- Cerebral amyloid angiopathy (CAA)
- Dementia with Lewy Bodies (DLB)
- Frontotemporal dementia (FTD)
- Movement disorders other than PD (Tics, Restless Legs Syndrome, Dystonia)
- Depression and psychotic states in AD/PD
- Neurodevelopment and neurodegeneration
- Head injury
- Cognitive impairments in autoimmune disorders
- Amyotrophic lateral sclerosis (ALS) and Huntington's Disease (HD)
- Multiple systems atrophy
- Progranulinopathies and other Protein Misfolding Diseases (PMD)
B. Genetics of neurodegenerative diseases
C. Pharmacogenomics in prevention and treatment
D. Epidemiology, pharmacoeconomics and quality of life
E. Neuroimaging
F. Biomarkers and diagnostics in prevention and treatment
G. CNS-periphery communication in neurodegenerative diseases
H. Biology of APP, Abeta, Abeta oligomers and beta- amyloid
I. Tau, cytoskeleton and tauopathies
J. Energy metabolism and oxidative stress
K. Apolipoprotein-E
L. Inflammation
M. Synucleopathies
N. Animal models of neurodegenerative diseases
O. Treatment and Disease Modification Strategies:
- Modulation of secretases
- Aggregation inhibitors
- Modulation of kinases and phosphatases
- Neurotransmitter-based treatments
- Cholesterol and lipids
- Low molecular weight glycosaminoglycans (GAGs) and GAG-mimetics
- Neurotrophic factors and inhibitors
- Immunotherapies and antibodies
- Stem cells
- Gene therapies
- New drug delivery systems/ methods
- Neurotransplantation and neurosurgery
- Novel pharmacological compounds
- Novel biological agents
P. Drug discovery and development
Q. Late breaking results
Alzheimer's Conference / Parkinson's Conference, Prague 2009